Benjamin WYPLOSZ
Le Kremlin-Bicêtre, 94270, France
NCT Number: NCT04968886
The objective of the present study is to confirm in a multicentric study the utility of our viability test in large cohort of smear-positive pulmonary tuberculosis patients under treatment and to determine if the test could help physicians to discontinue isolation measures in hospital setting.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Le Kremlin-Bicêtre, 94270, France
When patients with pulmonary tuberculosis (TB) are hospitalized for diagnosis and treatment, isolation measures are mandatory in order to prevent transmission. Recommendations are to maintain isolation until patients are no more infectious, which is ascertained when cultures of respiratory specimens become negative (culture conversion). After administration of antibiotics, the average time to culture conversion is one month for patients with drug-susceptible TB, but 5%-30% cases require more than two months and up to 6 months can be required for multiresistant (MDR)-TB.
Microscopic examination of bacilli in respiratory samples is mainly used as a surrogate marker but because bacilli staining does not differentiate alive from dead bacilli, the interpretation of positive smears is misleading. After 1-2 months of treatment, bacilli can be considered dead while they are still alive and isolation measures are thus erroneously discontinued. Conversely, bacilli can be considered viable while they have already been killed by the treatment and patients kept inadequately in isolation.
To overcome the misleading results, attempts have been made to develop viability biomarkers for Mycobacterium tuberculosis (Mtb), the agent of tuberculosis. Studies using RNA or DNA gave convincing results but their cost is not affordable in most part of the world. Those using fluorescein probes are easiest but studies have shown either conflicting results, or have been evaluated only for a short period of time after initiation of therapy.
Thus, we evaluated a fluorescent staining able to differentiate dead bacilli from alive, which was previously used for detection of industrial environmental pathogens - the Live/Dead® BacLight™ Bacterial viability test (Invitrogen, Biocentric, France). Briefly, the test permits to visualize the bacteria using SYTO-9 and propidiumiodide (PI) fluorescent dyes, which both bind to DNA but penetrate specifically cytoplasmic membrane: SYTO-9 penetrates all bacilli, either viable or not, whereas the PI penetrates only in cells with damaged membrane. Consequently, the viable bacteria are impermeable to PI and only fluoresced due to SYTO-9 appearing green under the fluorescent microscope, whereas dead bacteria are marked by both fluorescent dyes and appear red.
We firstly adapted the kit to mycobacteriology and assessed, in in vitro experiments, the concordance of the test with the culture results. Then, we showed in an observational prospective study its accurateness to predict culture results in patients undergoing antituberculous therapy: the viability test correctly predicted all culture-positive samples in the first two months after treatment.
The objective of the present study is to confirm in a multicentric study the utility of our viability test in large cohort of smear-positive pulmonary tuberculosis patients under treatment and to determine if the test could help physicians to discontinue isolation measures in hospital setting.
Since the test is quick (less than 1 h for the test versus a median of 23 days for culture) and easy to perform, it would be useful to help physicians to maintain isolation in clinical settings while avoiding unnecessary cultures. Since the test is also cheap (<1 € for reagents) this issue could be particularly valuable in countries with limited resources and where cultures are unavailable.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
Time frame: 12 months
The culture will be judged positive in case of isolation of tubercle bacilli in solid or liquid medium and will be judged negative if the culture is sterile after 42 days of incubation in liquid medium and 60 days in solid medium. If the culture is contaminated with bacteria other than tubercle bacilli, it will be considered uninterpretable.
Each test will be interpreted blind to the results of the other and the results of the TVmol. the diagnostic indices of the microscopic viability test will be calculated
Time frame: 12 months
Using real-time Polymerase Chain Reaction amplification in comparison with the bacterial culture (reference test).
Time frame: 12 months
Microscopic viability test expressed as the number of fluorescent green bacilli, and culture results expressed in number of colonies for culture in solid medium and Molecular viability test expressed in number of amplification cycles to reach the positivity threshold and in molecular concentration of the target gene and the culture results expressed
Time frame: 12 months
Evaluate the potential benefit of viability tests for the patient and the hospital over the duration of isolation and the time to discharge from hospital
Time frame: 12 months
Describe the cohort of patients hospitalized for pulmonary tuberculosis with positive microscopic examination in the 10 participating centers
Assistance Publique - Hôpitaux de Paris
Other
Multicenter Prospective Evaluation of Rapid Viability Tests for Mycobacterium Tuberculosis to Improve the Follow-up of Tuberculosis Patients and Guide Isolation Measures
Acronym: TBVISA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05007821
Actinomycetales Infections, Bacterial Infections
Gaborone, South-East District, Botswana
View Trial DetailsNCT04752592
Actinomycetales Infections, Bacterial Infections
Awasa, Ethiopia
View Trial DetailsNCT03512249
Actinomycetales Infections, Bacterial Infections
Bellville, Cape Town, South Africa
View Trial DetailsNCT05455112
Actinomycetales Infections, Bacterial Infections
Godoy Cruz, Mendoza Province, Argentina
View Trial Details